- Home
- SRG vs NTHI Comparison
SRG vs NTHI Comparison
Compare SRG & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$3.35
HOLD
Current Price
$7.02
Company Overview
Basic Information| Metric | SRG | NTHI |
|---|---|---|
| Founded | 2014 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 236.0M | 195.5M |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | SRG | NTHI |
|---|---|---|
| Price | $3.35 | $7.02 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 176.4K | 71.7K |
| Earning Date | 11-14-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $17,406,000.00 | $59,990.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.43 | $3.20 |
| 52 Week High | $4.56 | $25.00 |
Technical Indicators
Market Signals| Indicator | SRG | NTHI |
|---|---|---|
| Relative Strength Index (RSI) | 39.26 | 37.53 |
| Support Level | $3.38 | $8.63 |
| Resistance Level | $3.68 | $10.44 |
| Average True Range (ATR) | 0.13 | 0.93 |
| MACD | 0.00 | -0.18 |
| Stochastic Oscillator | 16.33 | 14.85 |
Price Performance
Historical Comparison SRG
NTHI
About SRG Seritage Growth Properties
Seritage Growth Properties is principally engaged in the ownership, development, redevelopment, management, and leasing of diversified and mixed-use properties throughout the United States.
About NTHI NeOnc Technologies Holdings Inc.
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA).